A law signed in 2023 caps out-of-pocket costs for insulin, asthma inhalers, and epinephrine injectors beginning Jan. 1.

Currently indicated to improve glycemic control in adults with diabetes, the company announced 6-month results from its Phase 3 INHALE-1 study of inhaled human insulin in children and adolescents ...

The inhaler - by which a spray deposits insulin directly into the lungs - is being tested in the UK after successful experiments in Canada. The spray could be a lifesaver for thousands of ...

For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol, according to ...

‘A breath of fresh air for #diabetes_management! Inhaled #insulin, #Afrezza, is now available in #India, thanks to #Cipla. #diabetes’ The company noted that Afrezza will start working in as ...

“We are excited for Cipla to market the first inhaled insulin treatment option for adults living with diabetes in India and expect to prepare product for export by the end of 2025.” MannKind ...

MannKind Corporation is a biopharmaceutical focusing on inhaled therapies for endocrine ... an insulin human inhalation powder for adults with diabetes mellitus type 2 [T2D].